Press Release
Attacks Continue on Mifepristone Access as Case is Transferred to Missouri
Washington, DC — Last night, Judge Matthew Kacsmaryk transferred Missouri v. FDA from his court in the Northern District of Texas to the Eastern District of Missouri. This move ensures the case, which challenges the Food and Drug Administration’s authority to regulate Mifepristone, will continue in a district packed with anti-abortion judges who were appointed by Trump.
Reproductive Freedom for All President and CEO Mini Timmaraju released the following statement:
“This case should never have been brought in the first place. Moving it to Missouri is part of the anti-abortion extremists’ relentless campaign to weaponize the courts against abortion access. Mifepristone has been safely used by millions for more than two decades and remains under threat because anti-abortion politicians are determined to ban and restrict it everywhere, even in states where abortion is protected. This is yet another blatant attempt at forcing a backdoor abortion ban.”
Mifepristone is safe and effective, and is used for medication abortion care and miscarriage care. Over the weekend, we marked the 25-year anniversary of Mifepristone being approved by the FDA. Read more about all the research behind Mifepristone’s efficacy, and the ongoing threats to Mifepristone here.
###
For over 55 years, Reproductive Freedom for All (formerly NARAL Pro-Choice America) has fought to protect and advance reproductive freedom at the federal and state levels—including access to abortion care, birth control, pregnancy and post-partum care, and paid family leave—for everybody. Reproductive Freedom for All is powered by its more than 4 million members from every state and congressional district in the country, representing the 8 in 10 Americans who support legal abortion.